MannKind Corporation Share Price Nasdaq
Stocks
US56400P2011
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 121.86Cr 105Cr 99Cr 90Cr 169.06Cr 12TCr 169.91Cr 1.18TCr 454.06Cr 5.92TCr 457.67Cr 447.63Cr 19TCr | P/E 2026 * |
-20.8x | P/E 2027 * | -3,032x |
|---|---|---|---|---|---|
| Enterprise Value | 121.86Cr 105Cr 99Cr 90Cr 169.06Cr 12TCr 169.91Cr 1.18TCr 454.06Cr 5.92TCr 457.67Cr 447.63Cr 19TCr | EV / Sales 2026 * |
2.75x | EV / Sales 2027 * | 2.42x |
| Free-Float |
98.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : MannKind Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 25/05/2017 |
| Director of Finance/CFO | 50 | 22/04/2024 | |
Ajay Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Consiglio
BRD | Director/Board Member | 82 | 01/10/2003 |
Michael Friedman
BRD | Director/Board Member | 82 | 01/12/2003 |
James Shannon
CHM | Chairman | 69 | 09/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.11% | -3.44% | +41.04% | +98.48% | 6.82TCr | |
| -0.23% | -4.45% | +30.39% | +73.64% | 6.22TCr | |
| -0.06% | +0.59% | -12.86% | +379.36% | 2.78TCr | |
| -1.05% | -7.30% | +25.00% | +12.31% | 2.49TCr | |
| +0.82% | -6.16% | -6.66% | -17.45% | 2.42TCr | |
| +0.43% | -3.37% | +14.85% | -19.29% | 1.94TCr | |
| -3.03% | -5.19% | +192.88% | +340.13% | 1.73TCr | |
| -1.94% | -6.36% | -7.05% | +516.16% | 1.45TCr | |
| -2.24% | -4.49% | +44.25% | +156.30% | 1.42TCr | |
| Average | -1.04% | -3.96% | +35.76% | +171.07% | 3.03TCr | |
| Weighted average by Cap. | -0.98% | -3.80% | +32.80% | +135.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 44Cr 38Cr 36Cr 33Cr 62Cr 4.24TCr 62Cr 429.67Cr 165.23Cr 2.16TCr 166.54Cr 162.89Cr 6.81TCr | 50Cr 43Cr 41Cr 37Cr 70Cr 4.81TCr 70Cr 488.33Cr 187.78Cr 2.45TCr 189.27Cr 185.12Cr 7.74TCr |
| Net income | -5.72Cr -4.93Cr -4.66Cr -4.23Cr -7.93Cr -546.24Cr -7.97Cr -55Cr -21Cr -277.9Cr -21Cr -21Cr -878.15Cr | 27.12T 23.37T 22.13T 20.05T 37.62T 25.91L 37.81T 3L 1L 13.18L 1L 99.62T 41.65L |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
